Malaria und ihre Bedeutung in der Reisemedizin

Als eine der wichtigsten Infektionskrankheiten weltweit – mit hoher Morbidität und Mortalität v. a. in Afrika – hat die Malaria auch in der Reisemedizin eine herausragende Bedeutung. Dies betrifft sowohl Diagnose und Therapie von importierten Infektionen als auch die Beratung vor Tropenreisen. Dieser Beitrag erläutert die aktuellen Empfehlungen zu Diagnostik, Therapie und Prophylaxe sowie besondere Aspekte im Rahmen der COVID-Pandemie.

Abstract

Malaria remains one of the most important infectious diseases worldwide. The annual number of cases is currently estimated at around 240 million globally, of which more than 500,000 cases are fatal. The majority of malaria cases in Europe are imported from the African continent. Plasmodium falciparum, the causative agent of malaria tropica, causes 75–90 % of all infections imported to Germany. Artemisinin-based combination therapies are the standard treatment for uncomplicated malaria worldwide. In addition to uncomplicated malaria infections, Plasmodium falciparum can cause severe malaria, characterized by vital organ dysfunction and hyperparasitaemia. The treatment of choice for severe malaria is parenteral artesunate. For all patients presenting with febrile illness after a stay in a malaria-endemic area malaria must be ruled out immediately. Microscopy of the thick drop remains the gold standard for diagnosis in clinical routine.

Schlüsselwörter

Malaria - falciparum - Artemisinin - Plasmodium - Artesunat

Key words

malaria - falciparum - artemisinin - plasmodium - artesunate

Publication History

Article published online:
07 June 2022

• Literatur

• 1 World Health Organization (WHO), Global Malaria Programme. World malaria report. 2021 Im Internet (Stand: 19.04.2022): https://apps.who.int/iris/rest/bitstreams/1398397/retrieve
• 2 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2020. Berlin: 2021 Im Internet (Stand: 19.04.2022): www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2020.pdf?__blob=publicationFile
• 3 Khatamazas E, Berkunova A, Denkinger C. et al. Reisekrankheiten: Malaria nicht vergessen. Dtsch Arztebl 2021; 118 (40) A-1822/B-1506 . Im Internet (Stand: 19.04.2022, accessed: 01/18/2022): www.aerzteblatt.de/archiv/221414/Reisekrankheiten-Malaria-nicht-vergessen
• 4 Mischlinger J, Rönnberg C, Álvarez-Martínez MJ. et al. Imported malaria in countries where malaria is not endemic: A comparison of semi-immune and nonimmune travelers. Clin Microbiol Rev 2020; 33
• 5 Kurth F, Develoux M, Mechain M. et al. Severe malaria in Europe: an 8-year multi-centre observational study. Malar J 2017; 16: 57
• 6 Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. (DTG). Leitlinie: Diagnostik und Therapie der Malaria, 2021. AWMF-Register: 042-001. Im Internet (Stand: 19.04.2022): www.awmf.org/uploads/tx_szleitlinien/042-001l_S1_Diagnostik-Therapie-Malaria_2021-08.pdf
• 7 Chiodini PL. Malaria diagnostics: now and the future. Parasitology 2014; 141: 1873-1879
• 8 Mischlinger J, Pitzinger P, Veletzky L. et al. Validity and reliability of methods to microscopically detect and quantify malaria parasitaemia. Trop Med Int Health 2018; 23: 980-991
• 9 Murray CK, Gasser Jr RA, Magill AJ. et al. Update on rapid diagnostic testing for malaria. Clin Microbiol Rev 2008; 21: 97-110
• 10 Gendrot M, Fawaz R, Dormoi J. et al. Genetic diversity and deletion of Plasmodium falciparum histidine-rich protein 2 and 3: a threat to diagnosis of P. falciparum malaria. Clin Microbiol Infect 2019; 25: 580-585
• 11 Gillet P, Mori M, Van Esbroeck M. et al. Assessment of the prozone effect in malaria rapid diagnostic tests. Malar J 2009; 8: 271
• 12 Martiáñez-Vendrell X, Jiménez A, Vásquez A. et al. Quantification of malaria antigens PfHRP2 and pLDH by quantitative suspension array technology in whole blood, dried blood spot and plasma. Malar J 2020; 19: 12
• 13 Kurth F, Develoux M, Mechain M. et al. Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study. Clin Infect Dis 2015; 61: 1441-1444
• 14 Dondorp AM, Fanello CI, Hendriksen ICE. et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647-1657
• 15 Rothe C, Rosenbusch D, Alberer M. et al. Empfehlungen zur Malariaprophylaxe. Flugmed, Tropenmedizin, Reisemedizin – FTR 2021; 28: 162-198
• 16 Tickell-Painter M, Maayan N, Saunders R. et al. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev 2017; 10: CD006491
• 17 Vinnemeier CD, Rothe C, Kreuels B. et al. Response to fever and utilization of standby emergency treatment (SBET) for malaria in travellers to Southeast Asia: a questionnaire-based cohort study. Malar J 2017; 16: 44
• 18 Balikagala B, Fukuda N, Ikeda M. et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med 2021; 385: 1163-1171
• 19 Nussenzweig RS, Vanderberg J, Most H. et al. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967; 216: 160-162
• 20 World Health Organization (WHO). WHO recommends groundbreaking malaria vaccine for children at risk. 2021 Im Internet (Stand: 19.04.2022): www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk